Tivic Health Systems has appointed Michael K. Handley as Chief Executive Officer, effective immediately. He succeeds founding CEO Jennifer Ernst, who will remain involved to ensure a smooth leadership transition as the company embarks on its next growth phase.

Handley brings over two decades of executive leadership in biopharmaceuticals and medical devices, leading US approvals and commercial launches of 17 products that generated billions in revenue. His career includes tenures at Amgen and Genentech, where he navigated complex regulatory processes and scaled global commercial operations.

Under Handley’s leadership, Tivic will intensify its focus on late-stage immunotherapies, including Entolimod and Entolasta, while leveraging its newly launched contract biomanufacturing arm, Velocity Bioworks. This vertical integration aims to reduce costs, accelerate production timelines and strengthen supply chain security for the company’s pipeline.